[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100536269":3},{"organization":4,"outcomesModule":7,"designInfo":53,"detailedDescription":59,"studyPopulation":52,"armGroups":60,"interventions":67,"overallOfficials":72,"centralContacts":76,"locations":81,"responsibleParty":96,"collaborators":99,"id":109,"slug":110,"hasResults":111,"nctId":112,"briefTitle":113,"officialTitle":114,"acronym":52,"eligibilityCriteria":115,"healthyVolunteers":111,"sex":116,"minAge":117,"maxAge":52,"enrollmentInfo":118,"targetDuration":52,"studyType":121,"phases":122,"briefSummary":123,"conditions":124,"keywords":52,"overallStatus":84,"whyStopped":52,"lastUpdateSubmitDate":126,"lastUpdatePostDateStruct":127,"startDateStruct":130,"completionDateStruct":132,"leadSponsor":134,"locationsCount":135},{"fullName":5,"class":6},"Chinese University of Hong Kong","OTHER",{"primaryOutcomes":8,"secondaryOutcomes":13,"otherOutcomes":52},[9],{"measure":10,"description":11,"timeFrame":12},"The oncological control of prostate cancer","Any clinically significant PCa (csPCa) detected on biopsy of treated area(s) per patient at 12 months after treatment, defined by:\n\n• ISUP grade group 2 or above PCa","At 12 months after treatment",[14,17,20,22,26,30,34,37,40,43,46,49],{"measure":15,"description":16,"timeFrame":12},"Clinically significant cancer detection on biopsy of each ablated MRI visible lesion","Per-lesion analysis of csPCa detected on biopsy of any ablated areas at 12 months",{"measure":18,"description":19,"timeFrame":12},"Cancer detection on biopsy of each ablated MRI invisible lesion","Per-lesion analysis of any cancer detected on biopsy of any ablated areas at 12 months",{"measure":21,"description":21,"timeFrame":12},"Out-of-field recurrence: Any cancer outside treated area on systematic biopsy",{"measure":23,"description":24,"timeFrame":25},"Common Terminology Criteria for Adverse Events (CTCAE) v5.0","Complications of treatment using Common Terminology Criteria for Adverse Events (CTCAE) v5.0","At 3 Month, 6 Month and 12 Month",{"measure":27,"description":28,"timeFrame":29},"PSA change","PSA change after treatment","At baseline, 3 Month and 6 Month and 12 Month",{"measure":31,"description":32,"timeFrame":33},"Urinary Symptoms after treatment","Urinary symptoms measured by IPSS score, score ranging from 0-35 (the higher the worse)","At baseline, 3 Month, 6 Month and 12 Month",{"measure":35,"description":36,"timeFrame":33},"Sexual side effects after treatment","Sexual side effects, up to 1 year, measured by IIEF-5 score (ranging from 1-25), the lower the worse",{"measure":38,"description":39,"timeFrame":33},"Continence side effects after treatment","Continence side effects, up to 1 year, measured by EPIC-26 questionnaire, the lower score the worse",{"measure":41,"description":42,"timeFrame":33},"Common Terminology Criteria for Adverse Events (CTCAE) rectal toxicity","Rectal toxicity of treatment using Common Terminology Criteria for Adverse Events",{"measure":44,"description":45,"timeFrame":33},"Quality of life measured by ED-5Q-5Lquestionnaire","Quality of life measured by ED-5Q-5L questionnaire, the higher the score the better in quality of life",{"measure":47,"description":48,"timeFrame":33},"Quality of life in patients with prostate cancer measured by EPIC-26","Quality of life in patients with prostate cancer measured by EPIC-26 range 0-100, the higher score the better the quality of life",{"measure":50,"description":51,"timeFrame":33},"Quality of life measured by QLQ-C30","Quality of life measured by QLQ-C30, score 0-100, the higher the score the better in quality of life",null,{"allocation":54,"interventionModel":55,"interventionModelDescription":52,"primaryPurpose":56,"observationalModel":52,"timePerspective":52,"maskingInfo":57},"NA","SINGLE_GROUP","TREATMENT",{"masking":58,"maskingDescription":52,"whoMasked":52},"NONE","This is a prospective multi-centre trial in 5 hospitals in 4 countries to investigate the efficacy and complications of TMA as a minimally invasive focal therapy for PCa. Men aged ≥50 with PSA \\\u003C 20ng\u002FmL, 1-2 MRI lesions with maximal dimension ≤15mm and ISUP grade group 2-3 PCa will be recruited. Transperineal TMA of the prostate tumor(s) will be done with repeated ablations by a single microwave needle guided by MRI-Ultrasound fusion and OBT navigation. The primary outcome is any clinically significant PCa (csPCa) detected on biopsy of treated area(s) per patient at 12 months.",[61],{"label":62,"type":63,"description":64,"interventionNames":65},"Targeted Microwave Ablation (TMA)","EXPERIMENTAL","Targeted Microwave Ablation (TMA) for localized prostate cancer using organ based tracking (OBT) navigation",[66],"Device: Targeted Microwave Ablation (TMA) for localized prostate cancer using organ based tracking (OBT) navigation",[68],{"type":69,"name":64,"description":70,"armGroupLabels":71,"otherNames":52},"DEVICE","Targeted microwave ablation (TMA) is a novel treatment developed for focal treatment of prostate cancer, and it is applied with precise navigation guidance under the organ-based tracking (OBT) mechanism.",[62],[73],{"name":74,"affiliation":5,"role":75},"Peter Ka-Fung CHIU, PhD,MBChB","PRINCIPAL_INVESTIGATOR",[77],{"name":74,"role":78,"phone":79,"phoneExt":52,"email":80},"CONTACT","35052625","peterchiu@surgery.cuhk.edu.hk",[82],{"facility":83,"status":84,"city":85,"state":52,"zip":52,"country":86,"countryCode":87,"cosmosGeoPoint":88,"geoPoint":93,"contacts":94},"Peter Ka-Fung CHIU","RECRUITING","Shatin","Hong Kong","HK",{"type":89,"coordinates":90},"Point",[91,92],114.18333,22.38333,{"lat":92,"lon":91},[95],{"name":74,"role":78,"phone":79,"phoneExt":52,"email":80},{"type":75,"investigatorFullName":97,"investigatorTitle":98,"investigatorAffiliation":5,"oldNameTitle":52,"oldOrganization":52},"CHIU Ka Fung Peter","Professor",[100,103,105,107],{"name":101,"class":102},"Princess Margaret Hospital, Hong Kong","OTHER_GOV",{"name":104,"class":6},"Siriraj Hospital",{"name":106,"class":6},"Universiti Putra Malaysia",{"name":108,"class":6},"Chinese General Hospital and Medical Center, Philippines","100536269","a-multi-centre-trial-on-targeted-microwave-ablation-tma-for-localized-prostate-cancer-100536269",false,"NCT06262633","A Multi-centre Trial on Targeted Microwave Ablation (TMA) for Localized Prostate Cancer: The VIOLETTA Trial","A Multi-centre Trial on Targeted Microwave Ablation (TMA) for Localized Prostate Cancer Using Organ Based Tracking (OBT) Navigation: The VIOLETTA Trial","Inclusion criteria:\n\n(i) Men aged ≥50 years old (ii) Life expectancy \\> 10 years upon recruitment (iii) Able to understand the trial and can provide informed and written consent, dated and signed before the enrollment and before any exam required by the trial (iv) Localized intermediate risk prostate cancer diagnosed on MRI-Ultrasound fusion targeted biopsy (v) Organ-confined prostate cancer on MRI (vi) PSA \\\u003C 20 ng\u002FmL (vii) 1-2 MRI visible lesion present with maximal tumor dimension ≤15mm, with targeted biopsy showing:\n\n* ISUP grade group 2 or 3 PCa\n* Systematic biopsies showing grade group 1-3 PCa just next to the MRI lesion is allowed\n* Systematic biopsies showing grade group 1 PCa far away from the lesion is allowed\n\nExclusion criteria:\n\n(i) Patients not fit for general or spinal anaesthesia (ii) Patients unfit for MRI exam or MR gadolinium contrast (e.g. estimated glomerular filtration rate (eGFR) of \\\u003C50 ml\u002Fmin) (iii) Patients with coagulopathy that cannot be corrected (iv) Patients on anticoagulants or antiplatelets that cannot be stopped (Low dose Aspirin, e.g. 80-100mg, is acceptable and no need to stop before or during TMA treatment) (v) Patients with previous treatment of prostate cancer (vi) Patients with prior pelvic radiotherapy for prostate cancer or other cancer (vii) Patients with maximal length of target lesion \\>15mm (viii) Patients with MRI lesion within 10mm from rectum or 10mm from sphincter on MRI (ix) Patients with \\>2 areas (MRI-visible or invisible) of prostate cancer (x) Patients with Gleason score 4+4 or any Gleason pattern 5 cancer (xi) Patients with systematic cores showing any Gleason 4 pattern PCa which are not adjacent to the target lesions (1 core of Gleason 3 pattern PCa on systematic cores in contralateral lobe is acceptable) (xii) Patients with definite extracapsular disease on imaging (prostate capsular contact without definite extra-capsular extension is acceptable) (xiii) Patients with bladder pathology including bladder stone or bladder cancer (xiv) Patients with known urethral stricture","MALE","50 Years",{"count":119,"type":120},110,"ESTIMATED","INTERVENTIONAL",[54],"This study is to investigate the efficacy of Targeted Microwave Ablation (TMA) under MRI-Ultrasound fusion and organ-based tracking (OBT) navigation in localized prostate cancer (PCa) in a multi-centre trial.",[125],"Prostate Cancer","2026-11-04",{"date":128,"type":129},"2026-11-06","ACTUAL",{"date":131,"type":129},"2024-03-15",{"date":133,"type":120},"2029-10-31",{"name":5,"class":6},1]